NCT07680335Recruiting
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease (BRIDGE-AD2)
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary. Blood-based biomarkers (BBMs) are promising tools for detecting Alzheimer's disease (AD), with current research showing high concordance with cerebrospinal fluid (CSF) biomarkers and amyloid PET imaging. However, it remains unclear how physicians would value the availability of BBMs for AD in routine clinical practice. The investigators hypothesize that BBMs will benefit both patients and physicians in the diagnostic process within a memory clinic setting. This study aims to investigate clinical impact and diagnostic utility of blood-based biomarkers for AD in the diagnostic process of a memory clinic. The main objectives are to investigate change in diagnosis, diagnostic certainty and patient management, due to BBM results.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 550 (estimated)
- First submitted
- 4 Jun 2026
- Start date
- 17 Sept 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Alzheimercentrum Amsterdam
- Diseases
- Alzheimer disease
- NCT number
- NCT07680335
What you commit to
- Study type: Interventional
- Planned participants: 550
- From 17 Sept 2025 to the primary completion date, 31 Dec 2026
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous biomarker-confirmed diagnosis of AD.
- Alcohol or drug abuse to such an extent that treatment would be advisable.
Age
- Age under 55.
Other
- Patient is incapacitated, and is not able to judge consequences of participation.
Who the study is looking for
- Patient presents in memory clinic with cognitive complaints.
- The physician is concerned about underlying AD as etiology of the complaints.
- Adequate fluency in Dutch to understand informed consent procedure.
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Flevoziekenhuis Coordinator of this site? Confirm its status | Almere Stad | Netherlands | Recruiting |
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
| Spaarne Gasthuis Coordinator of this site? Confirm its status | Haarlem | Netherlands | Recruiting |
| Tergooi MC Coordinator of this site? Confirm its status | Hilversum | Netherlands | Recruiting |
| Frisius MC Coordinator of this site? Confirm its status | Leeuwarden | Netherlands | Recruiting |
| Dijklander Ziekenhuis Coordinator of this site? Confirm its status | Purmerend | Netherlands | Recruiting |
| Jeroen Bosch Ziekenhuis Coordinator of this site? Confirm its status | 's-Hertogenbosch | Netherlands | Recruiting |
| Elisabeth-Tweesteden Ziekenhuis Coordinator of this site? Confirm its status | Tilburg | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.